Some of the lysine and arginine methyltransferases widely studied in anti-cancer therapeutics include G9a, EZH2, DOT1L (disruptor of telomeric silencing 1-like protein) and PRMT1 (protein arginine methyltransferases 1), inhibitors of which are being extensively investigated [295]. The gene discussed is EHMT2; the disease is cancer.